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tients, high expression of ERCC1 was an independent prognostic factor 
for poor OS (p=0.046), along with male gender (p=0.033).
Conclusion: High expression of ERCC1 protein may be a useful 
predictor of poor outcome in SCLC patients treated with chemotherapy 
with or without radiotherapy, especially in limited stage SCLC.
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Background: To investigate whether excision repair cross-complemen-
tation group 1 (ERCC1) expression as determined immunohistochemi-
cally, single nucleotide polymorphisms (SNPs) in the ERCC1 gene, 
and mutations of epidermal growth factor receptor (EGFR) are related 
to the prognosis of curatively resected non-small-cell lung cancer 
(NSCLC), and whether these markers are related.
Methods: One-hundred and thirty-three consecutive patients with 
NSCLC who did not receive adjuvant chemotherapy after curative 
surgery were included in this study. Representative areas from for-
malin-ﬁxed parafﬁn-embedded tumor samples were chosen for tissue 
microarray analysis. Immunohistochemistry was performed for ERCC1 
and the median semiquantitative H-score was used as a cut-off. EGFR 
mutations (exons 18, 19, and 21) were analyzed by the direct sequenc-
ing of tumor samples. Two SNPs in the ERCC1 gene, C8092A and 
T19007C, were investigated on the tumor samples.
Results: ERCC1 expression was evaluable in 130 patients and ERCC1 
was found to be positive in 80 patients (61.5%). Moreover, ERCC1 
was expressed more frequently in smokers and in squamous cell 
carcinomas. Patients with positive ERCC1 expression survived longer 
(median overall survival 2,742 days for ERCC1-positive vs. 1,423 
days for ERCC1-negative, P=.0463). EGFR mutations were found in 
27 patients (20.3%) but they were not found to affect overall survival. 
Interestingly, EGFR mutations were more frequent in ERCC1-negative 
tumors (12.5% in ERCC1-positive vs. 30% in ERCC1-negative tumors, 
P=.014). The SNPs in the ERCC1 gene were not associated with 
ERCC1 expression of the tumors and did not affect overall survival of 
the patients.
Conclusions: ERCC1 expression was identiﬁed as a prognostic marker 
of longer survival in resected NSCLCs. In addition, EGFR mutations 
were more frequently found in ERCC1-negative tumors, but were not 
found to affect survival in our patient group. 
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Background: Impaired signal transduction is associated with tumori-
genesis and progression of many kinds of human cancers. Transform-
ing growth factor (TGF)-beta/Smad and ras-mitogen activated protein 
kinase (MAPK) are two major signal transduction pathways for cells 
proliferation and differentiation, which transmit signals from the cell 
membrane to the nucleus. Activation of these two pathways may 
involve in malignant transformation. Although many researchers have 
assumed a role for deregulation of the Smads and MAPK pathways 
in the development of malignancy, only a few studies have looked at 
the Smad4 and MAPK activity in human lung cancers. Therefore, we 
detected the expression of Smad4, MAPK proteins (p38, ERK1/2 and 
JNK1) in NSCLC, and investigated their clinical signiﬁcance, espe-
cially with the prognosis. 
Methods: 71 primary non-small cell lung cancers (NSCLC) and paired 
lung normal tissues from the same patients were subject to investiga-
tion. These patients underwent surgery in 2001 and had been followed 
up for over 5 years. The expression of Smad4, p38, ERK1/2, JNK1 and 
their corresponding phosphorylated forms were detected using Western 
blot analysis of tissue homogenate from resected NSCLC and matched 
normal lung tissue. Immunohistochemical analysis was used to conﬁrm 
the cellular localization of the activated MAPKs and Smad4 in lung 
cancer cells. Using statistical analysis, we investigated the relationship 
among MAPKs, Smad4 and the clinicohistopathological factors, and 
their correlation with clinical prognosis.
Results: We found that only activated p38 (p-p38) was consistently 
increased in tumor compared with normal tissue, while Smad4 was 
signiﬁcantly decreased in lung cancer tissues than normal tissues (both 
p<0.05). Immunohistochemical analysis conﬁrmed the cellular localiza-
tion of the activated p38 in both the cytoplasm and nucleus, and Smad4 
in the nucleus only. Of various clinicohistopathological factors, the 
pathological staging (p-staging) was closely associated with the expres-
sion of p-p38 (P=0.000), p-ERK1/2(P=0.000), p-JNK1 (P=0.000) and 
Smad4 (P=0.005). Moreover, JNK1 is also correlated with the tumor 
location (P=0.028). The expression of Smad4 was inversely correlated 
with p-p38 (P=0.000) while no signiﬁcant correlation with ERK1/2 
and JNK1 (p=0.073, 0.451, respectively). Univariate analysis revealed 
worse prognosis in NSCLC patients with negative expression of 
Smad4, positive expression of p-p38 and p-JNK1 (P=0.0001, 0.0000, 
0.0208, respectively). And tumor differentiation and p-staging were 
signiﬁcantly correlated with the prognosis of NSCLC. While using 
multivariate analysis, only Smad4, p38, tumor differentiation and p-
staging were correlated with the prognosis (P=0.019, 0.044, 0.003, and 
0.020, respectively). Furthermore, the negative expression of p38 and 
positive expression of Smad4 were associated with a better prognosis 
of NSCLC, compared with the other combinations of p-p38 and Smad4 
(P=0.000). 
Conclusions: Therefore, we believe that Smad4 and p38 could be of 
importance in the signal transduction pathways for the initiation and 
development of NSCLC. Smad4 and p38 could be possibly used as 
prognostic factors for NSCLC. 
